Today, MolMed, an Italian pharmaceutical company, released results from its NGR-hTNF for mesothelioma clinical trial. While the trial, which enrolled 400 pleural mesothelioma patients, demonstrated no increases in overall survival of the entire population, it did show an improvement in survival for those patients with a poorer prognosis and whose disease had progressed between first-line […]
From the Meso Foundation Staff
On April 8 at 9 PM Eastern time, the Mesothelioma Applied Research Foundation (Meso Foundation) will hold a new installment of its ‘Meet the Experts’ series, featuring Dr. Joanna C. Horobin, the Chief Medical Officer at Verastem, Inc., who will discuss the company’s latest investigational agent, defactinib, which is being developed for use in patients with pleural […]
Following the successful conclusion of its annual Symposium, the Mesothelioma Applied Research Foundation (Meso Foundation) announced that later this year it will be the host of two regional conferences in Philadelphia and Chicago, for mesothelioma patients, their families, and others interested in learning about the most up-to-date information on mesothelioma treatment. In a cancer like mesothelioma, for […]
During the first week of April, the Mesothelioma Applied Research Foundation (Meso Foundation) will observe Asbestos Awareness Week while raising awareness of the deep damage inflicted by asbestos’ use and the overdue need for life-saving treatments and a cure for those who have already developed, or who will develop, mesothelioma. Mesothelioma is a cancer known to be caused by […]
by Mary Hesdorffer, NP, Executive Director of the Meso Foundation
It feels like a time warp as we move from project to project, one day blending into the next. We are deeply immersed in planning three regional conferences before this year ends, and projecting what is in store for us in 2015.
I would like to take […]